U.S. to Buy More Doses of COVID-19 Antibody Drug From GSK, Vir

GlaxoSmithKline (GSK) and Vir Biotechnology said they have secured contracts with the U.S. government worth an estimated $1 billion to supply doses of their COVID-19 antibody treatment, sotrovimab.

The FDA granted Emergency Use Authorization for sotrovimab in May based on results from a late-stage trial that showed it reduced the risk of death by 79 percent in adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease.

The companies said they will supply an unspecified number of doses by mid-December and that the government has an option to purchase additional doses through March 2022.